Who is ITB-MED
ITB-MED is developing the proprietary antagonistic CD2-directed monoclonal antibody, TCD601 (siplizumab), for several indications. ITB-MED is wholly committed to advancing and exploring t...
Read More
-
Headquarters: 110 E 59th St, New York, New York, 10022, United States
-
Date Founded: 2016
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8721
ITB-MED Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ITB-MED
Answer: ITB-MED's headquarters are located at 110 E 59th St, New York, 10022, United States
Answer: ITB-MED's official website is https://itb-med.com
Answer: ITB-MED's revenue is $1 Million to $5 Million
Answer: ITB-MED's SIC: 8721
Answer: ITB-MED has 11-50 employees
Answer: ITB-MED is in Biotechnology
Answer: ITB-MED contact info: Phone number: Website: https://itb-med.com
Answer: ITB-MED is developing the proprietary antagonistic CD2-directed monoclonal antibody, TCD601 (siplizumab), for several indications. ITB-MED is wholly committed to advancing and exploring the potential of TCD601, with a particular focus on its applications in transplantation and autoimmunity. The efforts extend to comprehensive worldwide clinical trials. ITB-MED is actively investigating further preclinical therapies to expand the reach of its novel immune-modulating approaches.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month